Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.69 |
| ▸ | ME2 | P23368 | 1/20 | 0.64 |
| ▸ | ME1 | P48163 | 1/20 | 0.64 |
| ▸ | ME3 | Q16798 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.61 |
| ▸ | GPX4 | P36969 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9987526 | 0.87 | KMT2A (0.68) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL10981623 | 0.86 | ME2 (0.64) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL12916359 | 0.85 | HTT (0.59) | AKR1C3GFERSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2878977 | 0.85 | POLB (0.69) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL7561191 | 0.85 | AKR1C3 (0.68) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL12419699 | 0.85 | AKR1C3 (0.68) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL3299369 | 0.84 | MAPT (0.70) | GFERSMN1; SMN2KMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL6910714 | 0.83 | AKR1C3 (0.66) | AKR1C3ME2ME1ME3GFER | |
| SCHEMBL264542 | 0.82 | MEN1 (0.74) | SMN1; SMN2KMT2AMEN1ALDH1A1HTR1A | |
| SCHEMBL12916410 | 0.81 | AKR1C3 (0.48) | AKR1C3ME2ME1ME3GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| WO-2022129256-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-06-23 | — | — | WO | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | Kineta, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| EP-2707101-B1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | AKR1C3 1322/4885ME2 1595/4885ME1 1855/4885 |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | AKR1C3 1908/4885ME2 4171/4885ME1 3290/4885 |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | AKR1C3 64/4885ME2 515/4885ME1 283/4885 |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | AKR1C3 64/4885ME2 515/4885ME1 283/4885 |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | AKR1C3 1322/4885ME2 1595/4885ME1 1855/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AKR1C3 1908/4885ME2 4171/4885ME1 3290/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AKR1C3 1971/4885ME2 4209/4885ME1 3024/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AKR1C3 1971/4885ME2 4209/4885ME1 3024/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | AKR1C3 64/4885ME2 515/4885ME1 283/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AKR1C3 1908/4885ME2 4171/4885ME1 3290/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | AKR1C3 64/4885ME2 515/4885ME1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.